HCPLive

MRI, PET, and CSF Biomarkers Improve Prediction of Alzheimer's Disease

 
WEDNESDAY, Dec. 12 (HealthDay News) -- Adding data from magnetic resonance imaging (MRI), fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers to routine clinical testing can improve the ability to predict conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), according to research published online Dec. 11 in Radiology.

Jennifer L. Shaffer, M.D., of Duke University Medical Center in Durham, N.C., and colleagues conducted a study involving 97 subjects with MCI who underwent MRI and FDG PET as well as CSF analysis to examine the extent to which multiple AD biomarkers predict future decline.

Compared with clinical testing alone, the researchers found that the combination of MRI, FDG PET, and CSF biomarker data correlated with a significant increase in the accuracy of predicting conversion to AD, with a decrease in the misclassification rate from 41.3 to 28.4 percent. Of the additional tests, FDG PET contributed more information to routine tests than either CSF or MRI data.

"In summary, a model combining clinical information with MRI, FDG PET, and CSF markers yielded the highest accuracy for predicting future MCI conversion. However, the most efficient model included only FDG PET with the clinical covariates," the authors write. "Thus, in patients with MCI in whom ApoE4 genotype and cognitive testing is already available, FDG PET would likely yield the greatest additional value."

Several authors disclosed financial ties to the pharmaceutical industry.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 

Most Popular

Recommended Reading

A recent study looked into the neural functions affected by ibuprofen and found some connections that may soon lead to a much greater understanding of the greatest pain mitigator of them all: the brain.
Discontinuation of multiple sclerosis medication saw nearly 2 in 5 patients experience some form of increased disease activity, according to research from NYU Langone Medical Center.
Weighing the pros and cons of prescription opioid use for chronic pain is an ongoing battle, and new research may have just added to the list of disadvantages.
There is considerable regional variation in thrombolysis treatment for ischemic stroke, according to a study published online June 2 in Stroke.

$vAR$